Overview

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib
Tremelimumab